|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schoen RE, Pinsky PF, Weissfeld JL,
Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys
SS, Crawford ED, et al: PLCO Project Team: Colorectal-cancer
incidence and mortality with screening flexible sigmoidoscopy. N
Engl J Med. 366:2345–2357. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mosli MH and Al-Ahwal MS: Colorectal
cancer in the Kingdom of Saudi Arabia: Need for screening. Asian
Pac J Cancer Prev. 13:3809–3813. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
De Rosa M, Rega D, Costabile V, Duraturo
F, Niglio A, Izzo P, Pace U and Delrio P: The biological complexity
of colorectal cancer: Insights into biomarkers for early detection
and personalized care. Therap Adv Gastroenterol. 9:861–886. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Keppler D, Sameni M, Moin K, Mikkelsen T,
Diglio CA and Sloane BF: Tumor progression and angiogenesis:
Cathepsin B & Co. Biochem Cell Biol. 74:799–810. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohamed MM and Sloane BF: Cysteine
cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer.
6:764–775. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gondi CS and Rao JS: Cathepsin B as a
cancer target. Expert Opin Ther Targets. 17:281–291. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marten K, Bremer C, Khazaie K, Sameni M,
Sloane B, Tung CH and Weissleder R: Detection of dysplastic
intestinal adenomas using enzyme-sensing molecular beacons in mice.
Gastroenterology. 122:406–414. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bengsch F, Buck A, Günther SC, Seiz JR,
Tacke M, Pfeifer D, von Elverfeldt D, Sevenich L, Hillebrand LE,
Kern U, et al: Cell type-dependent pathogenic functions of
overexpressed human cathepsin B in murine breast cancer
progression. Oncogene. 33:4474–4484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lim IT, Meroueh SO, Lee M, Heeg MJ and
Mobashery S: Strategy in inhibition of cathepsin B, a target in
tumor invasion and metastasis. J Am Chem Soc. 126:10271–10277.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schmitt M, Jänicke F, Moniwa N,
Chucholowski N, Pache L and Graeff H: Tumor-associated
urokinase-type plasminogen activator: Biological and clinical
significance. Biol Chem Hoppe Seyler. 373:611–622. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Emmert-Buck MR, Roth MJ, Zhuang Z, Campo
E, Rozhin J, Sloane BF, Liotta LA and Stetler-Stevenson WG:
Increased gelatinase A (MMP-2) and cathepsin B activity in invasive
tumor regions of human colon cancer samples. Am J Pathol.
145:1285–1290. 1994.PubMed/NCBI
|
|
15
|
Khan A, Krishna M, Baker SP and Banner BF:
Cathepsin B and tumor-associated laminin expression in the
progression of colorectal adenoma to carcinoma. Mod Pathol.
11:704–708. 1998.PubMed/NCBI
|
|
16
|
Adenis A, Huet G, Zerimech F, Hecquet B,
Balduyck M, Peyrat JP and Cathepsin B: Cathepsin BL, and D
activities in colorectal carcinomas: Relationship with
clinico-pathological parameters. Cancer Lett. 96:267–275. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Troy AM, Sheahan K, Mulcahy HE, Duffy MJ,
Hyland JM and O'Donoghue DP: Expression of Cathepsin B and L
antigen and activity is associated with early colorectal cancer
progression. Eur J Cancer. 40:1610–1616. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sinha AA, Gleason DF, Deleon OF, Wilson MJ
and Sloane BF: Localization of a biotinylated cathepsin B
oligonucleotide probe in human prostate including invasive cells
and invasive edges by in situ hybridization. Anat Rec. 235:233–240.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rempel SA, Rosenblum ML, Mikkelsen T, Yan
PS, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G and
Sloane BF: Cathepsin B expression and localization in glioma
progression and invasion. Cancer Res. 54:6027–6031. 1994.PubMed/NCBI
|
|
20
|
Matarrese P, Ascione B, Ciarlo L, Vona R,
Leonetti C, Scarsella M, Mileo AM, Catricalà C, Paggi MG and
Malorni W: Cathepsin B inhibition interferes with metastatic
potential of human melanoma: An in vitro and in vivo study. Mol
Cancer. 9:2072010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sevenich L, Schurigt U, Sachse K, Gajda M,
Werner F, Müller S, Vasiljeva O, Schwinde A, Klemm N, Deussing J,
et al: Synergistic antitumor effects of combined cathepsin B and
cathepsin Z deficiencies on breast cancer progression and
metastasis in mice. Proc Natl Acad Sci USA. 107:pp. 2497–2502.
2010; View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sevenich L, Werner F, Gajda M, Schurigt U,
Sieber C, Müller S, Follo M, Peters C and Reinheckel T: Transgenic
expression of human cathepsin B promotes progression and metastasis
of polyoma-middle-T-induced breast cancer in mice. Oncogene.
30:54–64. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gong F, Peng X, Luo C, Shen G, Zhao C, Zou
L, Li L, Sang Y, Zhao Y and Zhao X: Cathepsin B as a potential
prognostic and therapeutic marker for human lung squamous cell
carcinoma. Mol Cancer. 12:1252013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bian B, Mongrain S, Cagnol S, Langlois MJ,
Boulanger J, Bernatchez G, Carrier JC, Boudreau F and Rivard N:
Cathepsin B promotes colorectal tumorigenesis, cell invasion, and
metastasis. Mol Carcinog. 55:671–687. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chan AT, Baba Y, Shima K, Nosho K, Chung
DC, Hung KE, Mahmood U, Madden K, Poss K, Ranieri A, et al:
Cathepsin B expression and survival in colon cancer: Implications
for molecular detection of neoplasia. Cancer Epidemiol Biomarkers
Prev. 19:2777–2785. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Al Obeed OA, Alkhayal KA, Al Sheikh A,
Zubaidi AM, Vaali-Mohammed MA, Boushey R, Mckerrow JH and Abdulla
MH: Increased expression of tumor necrosis factor-α is associated
with advanced colorectal cancer stages. World J Gastroenterol.
20:18390–18396. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Leonard L, Gunderson, Jessup JM, Sargent
D, Greene F and Stewart Andrew: Revised TN categorization for colon
cancer based on national survival outcomes data. J Clin Oncol.
28:2010.PubMed/NCBI
|
|
28
|
Kos J, Nielsen HJ, Krasovec M, Christensen
IJ, Cimerman N, Stephens RW and Brünner N: Prognostic values of
cathepsin B and carcinoembryonic antigen in sera of patients with
colorectal cancer. Clin Cancer Res. 4:1511–1516. 1998.PubMed/NCBI
|
|
29
|
Sheahan K, Shuja S and Murnane MJ:
Cysteine protease activities and tumor development in human
colorectal carcinoma. Cancer Res. 49:3809–3814. 1989.PubMed/NCBI
|
|
30
|
Murnane MJ, Sheahan K, Ozdemirli M and
Shuja S: Stage specific increases in cathepsin B messenger RNA
content in human colorectal carcinoma. Cancer Res. 51:1 137–1142.
1991.
|
|
31
|
Tu C, Ortega-Cava CF, Chen G, Fernandes
ND, Cavallo-Medved D, Sloane BF, Band V and Band H: Lysosomal
cathepsin B participates in the podosome-mediated extracellular
matrix degradation and invasion via secreted lysosomes in v-Src
fibroblasts. Cancer Res. 68:9147–9156. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hirai K, Yokoyama M, Asano G and Tanaka S:
Expression of cathepsin B and cystatin C in human colorectal
cancer. Hum Pathol. 30:680–686. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Talieri M, Papadopoulou S, Scorilas A,
Xynopoulos D, Arnogianaki N, Plataniotis G, Yotis J and Agnanti N:
Cathepsin B and cathepsin D expression in the progression of
colorectal adenoma to carcinoma. Cancer Lett. 205:97–106. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shuja S, Sheahan K and Murnane MJ:
Cysteine endopeptidase activity levels in normal human tissues,
colorectal adenomas and carcinomas. Int J Cancer. 49:341–346. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Victor BC, Anbalagan A, Mohamed MM, Sloane
BF and Cavallo-Medved D: Inhibition of cathepsin B activity
attenuates extracellular matrix degradation and inflammatory breast
cancer invasion. Breast Cancer Res. 13:R1152011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Campo E, Muñoz J, Miquel R, Palacín A,
Cardesa A, Sloane BF and Emmert-Buck MR: Cathepsin B expression in
colorectal carcinomas correlates with tumor progression and
shortened patient survival. Am J Pathol. 145:301–309.
1994.PubMed/NCBI
|
|
37
|
Devetzi M, Scorilas A, Tsiambas E, Sameni
M, Fotiou S, Sloane BF and Talieri M: Cathepsin B protein levels in
endometrial cancer: Potential value as a tumour biomarker. Gynecol
Oncol. 112:531–536. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gopinathan A, Denicola GM, Frese KK, Cook
N, Karreth FA, Mayerle J, Lerch MM, Reinheckel T and Tuveson DA:
Cathepsin B promotes the progression of pancreatic ductal
adenocarcinoma in mice. Gut. 61:877–884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Konduri S, Lakka SS, Tasiou A, Yanamandra
N, Gondi CS, Dinh DH, Olivero WC, Gujrati M and Rao JS: Elevated
levels of cathepsin B in human glioblastoma cell lines. Int J
Oncol. 19:519–524. 2001.PubMed/NCBI
|
|
40
|
Withana NP, Blum G, Sameni M, Slaney C,
Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, et
al: Cathepsin B inhibition limits bone metastasis in breast cancer.
Cancer Res. 72:1199–1209. 2012. View Article : Google Scholar : PubMed/NCBI
|
